Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

93P - Identifying the origin of lung-specific cancer of unknown primary based on comprehensive genomic profiling optimized with DNA methylation

Date

16 Sep 2021

Session

ePoster Display

Topics

Translational Research

Tumour Site

Carcinoma of Unknown Primary Site (CUP)

Presenters

Yun Fan

Citation

Annals of Oncology (2021) 32 (suppl_5): S382-S406. 10.1016/annonc/annonc686

Authors

Y. Fan, K. Chen

Author affiliations

  • Department Of Medical Oncology, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 93P

Background

Precise diagnosis of the tissue origin for metastatic carcinoma is essential to decide the treatment scheme and improve outcome. The purpose of this study is to predict the primary site for lung-specific cancer of unknown primary (CUP) through genomic and DNA methylation profiles.

Methods

Comprehensive genomic profiling (CGP) was performed to determine the genomic status within individual paired intrapulmonary and extrapulmonary samples, and targeted bisulfite sequencing was exploited to interrogate their methylation status. Model training subjects consisted of lung cancer and another type of cancer to compute the prediction signature weights for each DMR feature.

Results

A total of 300 patients with multi-site malignancies including lung and other organ lesions were screened retrospectively. Excluding individuals clearly diagnosed with imaging modalities and IHC staining, 40 patients needed further differential diagnosis. Among them, 26 cases were identified with novel molecular events like EGFR or ALK alterations; the remaining 14 lung-specific CUPs were located with another type of caners in stomach (n=5), intestine (n=5) and cervix (n=4). Of the 14 CUP cases, mutation spectrum analyses could distinguish metastatic disease from multiple primary tumors, while it was hard to determine the origin of metastatic cancers. However, methylation profiles not only predicted the consistent results with mutation spectrum, but also identified the origin of tumors through our train classification models (AUC>0.98), which can be confirmed with patients’ clinical efficacy who received treatments guided by prediction signature. Collectively, compared with genomic profiles, DNA methylation profiling demonstrated better tumor traceability to determine the primary site of CUPs.

Conclusions

The signature based on within-sample CGP testing optimized with DNA methylation could exactly identify the origin of lung-specific CUPs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yun Fan.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.